Revolution Medicines Inc.
RVMD | NASDAQ
$188.17
-$3.14 (-1.64%)
At close: Nov 2, 2026, 4:00 PM ET
$190.00
-$1.31 (-0.68%)
Pre-market:
Nov 2, 2026, 9:27 AM ET
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 | Q4 2023 Dec 31, 2023 | Q3 2023 Sep 30, 2023 | Q2 2023 Jun 30, 2023 | Q1 2023 Mar 31, 2023 | Q4 2022 Dec 31, 2022 | Q3 2022 Sep 30, 2022 | Q2 2022 Jun 30, 2022 | Q1 2022 Mar 31, 2022 | Q4 2021 Dec 31, 2021 | Q3 2021 Sep 30, 2021 | Q2 2021 Jun 30, 2021 | Q1 2021 Mar 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 742K | 742K | 4.57M | 11.58M | 26.17M | 29.52M | 34.82M | 35.38M | 29.51M | 27.26M | 26.84M | 29.39M | 28.68M | 40.24M | 41.57M |
Cost of Revenue | 9.24M | 9.24M | 4.7M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -9.24M | -9.24M | -4.7M | n/a | n/a | n/a | n/a | 742K | 742K | 4.57M | 11.58M | 26.17M | 29.52M | 34.82M | 35.38M | 29.51M | 27.26M | 26.84M | 29.39M | 28.68M | 40.24M | 41.57M |
Operating Income | -1.63B | -1.39B | -1.18B | -1.04B | -897.5M | -789.43M | -689.52M | -653.2M | -600.73M | -552.89M | -487.19M | -368.91M | -322.19M | -275.49M | -258.28M | -249.48M | -226.11M | -208.56M | -188.01M | -169.18M | -143.56M | -127.01M |
Interest Income | 98.46M | 85.29M | 90.69M | 90.63M | 88.96M | 88.04M | 86.88M | 84.33M | 74.87M | 63.88M | 47.18M | 33.58M | 25.54M | 15.91M | 9.15M | 4.31M | 1.63M | 998K | 929K | 944K | 1.07M | 1.56M |
Pretax Income | -1.77B | -1.37B | -1.13B | -961.73M | -812.81M | -698.26M | -600.85M | -566.72M | -522.73M | -487.8M | -439.89M | -335.33M | -296.65M | -259.58M | -249.13M | -245.17M | -224.49M | -207.56M | -187.09M | -168.26M | -142.54M | -125.51M |
Net Income | -1.77B | -1.37B | -1.13B | -960.98M | -812.06M | -697.51M | -600.09M | -567.06M | -519.21M | -484.27M | -436.37M | -331.34M | -296.23M | -259.16M | -248.71M | -244.87M | -224.49M | -207.56M | -187.09M | -168.62M | -142.9M | -125.82M |
Selling & General & Admin | 328.54M | 258.91M | 192.67M | 156.57M | 127.77M | 108.9M | 96.72M | 100.75M | 92.31M | 85.24M | 75.62M | 54.29M | 49.21M | 44.77M | 40.59M | 38.37M | 35.72M | 32.82M | 30.45M | 27.58M | 25.13M | 22.93M |
Research & Development | 1.29B | 1.12B | 985M | 880.49M | 769.73M | 680.53M | 592.8M | 553.19M | 509.17M | 472.22M | 423.14M | 340.79M | 302.51M | 265.53M | 253.07M | 240.63M | 217.65M | 202.58M | 186.95M | 170.27M | 158.67M | 145.65M |
Other Expenses | -4.54M | -4.54M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 1.62B | 1.38B | 1.18B | 1.04B | 897.5M | 789.43M | 689.52M | 653.94M | 601.48M | 557.45M | 498.77M | 395.08M | 351.72M | 310.3M | 293.66M | 278.99M | 253.37M | 235.4M | 217.4M | 197.86M | 183.8M | 168.58M |
Interest Expense | 59.34M | 35.56M | 23.36M | 11.43M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 12K | 26K | 43K | 62K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 1.63B | 1.39B | 1.18B | 1.04B | 897.5M | 789.43M | 689.52M | 653.94M | 601.48M | 557.45M | 498.77M | 395.08M | 351.72M | 310.3M | 293.66M | 278.99M | 253.37M | 235.4M | 217.4M | 197.86M | 183.8M | 168.58M |
Income Tax Expense | n/a | n/a | n/a | -753K | -753K | -753K | -753K | 343K | -3.52M | -3.52M | -3.52M | -3.99M | -420K | -420K | -420K | -297K | n/a | n/a | n/a | 362K | 362K | 304K |
Shares Outstanding (Basic) | 210.89M | 198.1M | 190.13M | 189.23M | 188.15M | 188.15M | 167.74M | 166.84M | 165.14M | 164.73M | 141.18M | 109.23M | 106.88M | 94.83M | 89.16M | 84.69M | 74.28M | 74.16M | 73.82M | 73.54M | 73.4M | 70.42M |
Shares Outstanding (Diluted) | 210.89M | 198.1M | 190.13M | 189.23M | 188.15M | 188.15M | 167.74M | 166.84M | 165.14M | 164.73M | 141.18M | 109.23M | 106.88M | 94.83M | 89.16M | 84.69M | 74.28M | 74.16M | 73.83M | 73.54M | 73.4M | 70.42M |
EPS (Basic) | -8.86 | -7.11 | -5.95 | -5.18 | -4.51 | -4.01 | -3.58 | -3.59 | -3.64 | -3.75 | -3.67 | -3.16 | -3.04 | -2.93 | -3.08 | -3.16 | -3.01 | -2.80 | -2.56 | -2.37 | -2.07 | -1.93 |
EPS (Diluted) | -8.86 | -7.11 | -5.95 | -5.18 | -4.51 | -4.01 | -3.58 | -3.59 | -3.64 | -3.75 | -3.67 | -3.16 | -3.04 | -2.93 | -3.08 | -3.16 | -3.01 | -2.80 | -2.56 | -2.37 | -2.07 | -1.93 |
EBITDA | -1.7B | -1.32B | -1.09B | -935.06M | -799.03M | -685.48M | -589.02M | -526.62M | -483.36M | -449.45M | -401.77M | -326.28M | -287.31M | -249.68M | -239.47M | -236.05M | -216.05M | -199.62M | -179.75M | -161.26M | -135.65M | -118.77M |
EBIT | -1.71B | -1.34B | -1.11B | -950.3M | -812.81M | -698.26M | -600.85M | -537.91M | -493.92M | -458.99M | -411.08M | -335.33M | -296.65M | -259.58M | -249.13M | -245.17M | -224.49M | -207.56M | -187.08M | -168.23M | -142.5M | -125.45M |
Depreciation & Amortization | 13.58M | 17.38M | 16.56M | 15.24M | 13.78M | 12.78M | 11.82M | 11.3M | 10.56M | 9.54M | 9.31M | 9.05M | 9.34M | 9.9M | 9.66M | 9.12M | 8.44M | 7.94M | 7.33M | 6.97M | 6.85M | 6.68M |
Add to Watchlist
Select watchlists to add or remove RVMD